Promoter polymorphisms of TOP2A and ERCC1 genes as predictive factors for chemotherapy in non-small cell lung cancer patients

被引:25
作者
Grenda, Anna [1 ]
Blach, Justyna [1 ,2 ]
Szczyrek, Michal [1 ]
Krawczyk, Pawel [1 ]
Nicos, Marcin [1 ,3 ]
Kaminska, Barbara Kuznar [4 ]
Jakimiec, Monika [1 ]
Balicka, Grazyna [5 ]
Chmielewska, Izabela [1 ]
Batura-Gabryel, Halina [4 ]
Sawicki, Marek [5 ]
Milanowski, Janusz [1 ]
机构
[1] Med Univ Lublin, Dept Pneumonol Oncol & Allergol, Jaczewskiego 8, PL-20954 Lublin, Poland
[2] Med Univ Lublin, Dept Clin Immunol, Lublin, Poland
[3] Karolinska Inst, Dept Med Biochem & Biophys, Sci Life Lab, Stockholm, Sweden
[4] Poznan Univ Med Sci, Dept Pulmonol Allergol & Resp Oncol, Poznan, Poland
[5] Med Univ Lublin, Dept Thorac Surg, Lublin, Poland
来源
CANCER MEDICINE | 2020年 / 9卷 / 02期
关键词
ERCC1; non-small cell lung cancer; single-nucleotide polymorphisms; TOP2A; PLATINUM-BASED CHEMOTHERAPY; SINGLE NUCLEOTIDE POLYMORPHISMS; TOPOISOMERASE-II-ALPHA; DNA-DAMAGE RESPONSE; EXCISION-REPAIR; ASSOCIATION; SURVIVAL; PROGNOSIS; METABOLISM; EXPRESSION;
D O I
10.1002/cam4.2743
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Topoisomerase 2-alpha (TOP2A) is an enzyme that controls topologic changes in DNA during transcription and replication. ERCC1 is an enzyme that takes part in DNA repair processes. The purpose of this study was to assess the predictive role of particular single nucleotide polymorphisms (SNPs) in the promoter regions of TOP2A and ERCC1 genes in non-small cell lung cancer patients (NSCLC) treated with chemotherapy. Materials and methods We enrolled 113 NSCLC patients treated in the first line with platinum-based chemotherapy. Effectiveness was available for 71 patients. DNA was isolated from whole blood using the Qiamp DNA Blood Mini kit (Qiagen). We examined five SNPs: rs11615 (ERCC1), rs3212986 (ERCC1), rs13695 (TOP2A), rs34300454 (TOP2A), rs11540720 (TOP2A). Quantitative PCR using the TaqMan probe (ThermoFisher) was performed on a Eco Illumina Real-Time PCR system device (Illumina Inc). Results Patients with the A/A genotype in rs11615 of the ERCC1 gene had significantly longer median progression free survival (PFS) (8.5 months; P = .0088). Patients with the C/C genotype in rs3212986 of the ERCC1 gene had longer median PFS (7 months; P = .05). Patients with the C/C genotype in rs34300454 of TOP2A gene had significantly higher median PFS (7.5 months; P = .0029). Carriers of the C/C genotype in rs34300454 of the TOP2A gene had significantly longer median OS (15.5 months; P = .0017). Patients with the A/A genotype in rs11615 of the ERCC1 gene had significantly higher risk of neutropenia (P = .0133). Conclusions Polymorphisms of the TOP2A and ERCC1 genes may be a predictive factor of toxicities and survival for chemotherapy in NSCLC patients.
引用
收藏
页码:605 / 614
页数:10
相关论文
共 42 条
  • [31] Effects of excision repair cross-complementation group 1 (ERCC1) single nucleotide polymorphisms on the prognosis of non-small cell lung cancer patients
    Takenaka, Tomoyoshi
    Yano, Tokujiro
    Kiyohara, Chikako
    Miura, Naoko
    Kouso, Hidenori
    Ohba, Taro
    Kometani, Takuro
    Shoji, Fumihiro
    Yoshino, Ichiro
    Maehara, Yoshihiko
    [J]. LUNG CANCER, 2010, 67 (01) : 101 - 107
  • [32] Genetic Polymorphisms and Platinum-based Chemotherapy Treatment Outcomes in Patients with Non-Small Cell Lung Cancer: A Genetic Epidemiology Study Based Meta-analysis
    Tan, Li-Ming
    Qiu, Cheng-Feng
    Zhu, Tao
    Jin, Yuan-Xiang
    Li, Xi
    Yin, Ji-Ye
    Zhang, Wei
    Zhou, Hong-Hao
    Liu, Zhao-Qian
    [J]. SCIENTIFIC REPORTS, 2017, 7
  • [33] Introduction to The 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart
    Travis, William D.
    Brambilla, Elisabeth
    Burke, Allen P.
    Marx, Alexander
    Nicholson, Andrew G.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : 1240 - 1242
  • [34] Sequential assembly of the nucleotide excision repair factors in vivo
    Volker, M
    Moné, MJ
    Karmakar, P
    van Hoffen, A
    Schul, W
    Vermeulen, W
    Hoeijmakers, JHJ
    van Driel, R
    van Zeeland, AA
    Mullenders, LHF
    [J]. MOLECULAR CELL, 2001, 8 (01) : 213 - 224
  • [35] Theoretical models of DNA topology simplification by type IIA DNA topoisomerases
    Vologodskii, Alexander
    [J]. NUCLEIC ACIDS RESEARCH, 2009, 37 (10) : 3125 - 3133
  • [36] Association of Topoisomerase II (TOP2A) and Dual-Specificity Phosphatase 6 (DUSP6) Single Nucleotide Polymorphisms with Radiation Treatment Response and Prognosis of Lung Cancer in Han Chinese
    Wang, Tian-Lu
    Ren, Yang-Wu
    Wang, He-Tong
    Yu, Hong
    Zhao, Yu-Xia
    [J]. MEDICAL SCIENCE MONITOR, 2017, 23 : 984 - 993
  • [37] How Taxol/paclitaxel kills cancer cells
    Weaver, Beth A.
    [J]. MOLECULAR BIOLOGY OF THE CELL, 2014, 25 (18) : 2677 - 2681
  • [38] Predictive value of ERCC1 and XPD polymorphism in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: a systematic review and meta-analysis
    Wei, Shu-zhen
    Zhan, Ping
    Shi, Mei-qi
    Shi, Yi
    Qian, Qian
    Yu, Li-ke
    Song, Yong
    [J]. MEDICAL ONCOLOGY, 2011, 28 (01) : 315 - 321
  • [39] Association of ERCC1-C118T and-C8092A polymorphisms with lung cancer risk and survival of advanced-stage non-small cell lung cancer patients receiving platinum-based chemotherapy: A pooled analysis based on 39 reports
    Xu, Tong-Peng
    Shen, Hua
    Liu, Ling-Xiang
    Shu, Yong-Qian
    [J]. GENE, 2013, 526 (02) : 265 - 274
  • [40] The association between the GSTP1 A313G and GSTM1 null/present polymorphisms and the treatment response of the platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients: a meta-analysis
    Yang, Yanlong
    Xian, Lei
    [J]. TUMOR BIOLOGY, 2014, 35 (07) : 6791 - 6799